Drug Price Trends for ALAHIST CF TABLET

Average Pharmacy Cost for ALAHIST CF TABLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALAHIST CF TABLET	50991-0784-90	0.67164	EACH	2026-04-22
ALAHIST CF TABLET	50991-0784-90	0.67167	EACH	2026-03-18
ALAHIST CF TABLET	50991-0784-90	0.67076	EACH	2026-02-18
ALAHIST CF TABLET	50991-0784-90	0.67045	EACH	2026-01-21
ALAHIST CF TABLET	50991-0784-90	0.67008	EACH	2025-12-17
ALAHIST CF TABLET	50991-0784-90	0.67043	EACH	2025-11-19

Market Analysis and Price Projections for ALAHIST CF Tablet

Last updated: February 15, 2026

What is ALAHIST CF Tablet?

ALAHIST CF is a combination drug used primarily for allergic rhinitis and other allergic conditions. It combines an antihistamine with a decongestant, typically azelastine and pseudoephedrine. Its formulation aims to provide symptomatic relief of nasal congestion, sneezing, and runny nose.

Market Overview

Competitive Landscape

• Key competitors: Allergra (fexofenadine + pseudoephedrine), Claritin-D (loratadine + pseudoephedrine), and Nasal sprays like Flonase.
• Market size: The global allergy medication market was valued at approximately USD 16.6 billion in 2021 and is expected to grow at a 4-6% CAGR through 2028 (1).
• Brand presence: ALAHIST CF is marketed mainly in India and select Asian markets, where combination antihistamines with decongestants hold significant prescription volume due to allergy prevalence.

Regional Market Dynamics

• India: Estimated allergy medication market size is USD 1.2 billion, with high prescription rates for combination formulations.
• United States: Lower prescription volume due to preference for single-agent drugs, but high OTC sales potential.
• Emerging markets: Rapid growth driven by urbanization, pollution, and increasing awareness.

Market Demand Drivers

• Rising prevalence of allergic diseases globally, estimated at 10-30% of the population in developed and developing countries.
• Increased awareness leading to higher OTC and prescription volumes.
• Preference for combination therapies that address multiple symptoms simultaneously.

Regulatory Environment

• India: Drug approval process by CDSCO (Central Drugs Standard Control Organization). The drug must meet strict safety, efficacy, and manufacturing standards to gain market approval.
• United States & Europe: Regulatory pathways through FDA or EMA, respectively, with approval based on comprehensive clinical trial data.
• Pricing regulations: Often government-controlled in emerging markets; OTC classification influences retail pricing.

Price Projections

Current Price Benchmarks

• India (Rx): Publicly listed prices range from INR 70-120 for a 10-tablet pack (~USD 0.90-1.60).
• India (OTC): Retail prices may vary from INR 90-150 (~USD 1.20-2.00), influenced by market competition.
• United States: Estimated market price is USD 12-20 per tablet pack, with variations depending on formulation and pharmacy markups.

Forecast for the Next 3-5 Years

• India: Price stability expected due to minimal regulatory price controls on branded generics; however, increased competition and patent expiry could pressure prices downward by 10-15% annually.
• Emerging Markets: Prices are projected to remain relatively stable due to demand and limited competition, with a potential 5-10% annual increase driven by inflation and logistics costs.
• Developed Markets: OTC sales could see price inflation of 3-5% annually, influenced by pharmacy margins and consumer preferences.

Region	Current Price Range (USD)	Price Trend (Next 5 Years)	Influencing Factors
India	0.90 – 2.00	–10% to -15% annually due to competition	Patent expiries, generic proliferation, regulatory environment
US & Europe	12 – 20 per pack	+3% to +5% annually	Market demand, inflation, premium branding
Emerging Markets	1.20 – 2.00	+5% to +10% annually	Supply chain inflation, rising healthcare spending

Revenue Projections

• Market size: Combining regional sales assumptions, the global vendor could generate USD 300-500 million annually by 2028.
• Market share: Assuming steady growth and effective marketing, capturing 10-15% of the allergy combination market is feasible for a new entrant.

Risks

• Regulatory delays: Approval process can extend over 1-3 years, especially with complex formulations.
• Pricing pressures: Generic competition and price sensitivity in emerging markets can compress margins.
• Market penetration: Brand recognition and prescribing habits favor established brands; patient adherence can be a challenge.

---

Key Takeaways

• The global allergy medication market is expanding, with significant growth in emerging markets.
• In India, ALAHIST CF's price is around USD 1.20-2.00 per pack with potential downward pressure due to generics.
• In developed markets like the US and Europe, retail prices may reach USD 12-20 per pack, driven by OTC sales.
• Price trends over the next five years will be influenced by patent status, market competition, regulatory policies, and inflation.

FAQs

1. What factors most influence ALAHIST CF's market price?
   Pricing is affected by regional regulations, competition from generics, manufacturing costs, and demand elasticity.

2. How does patent expiry impact pricing?
   Patent expiration typically leads to increased generic competition, driving prices down by 10-15% annually in high-volume markets.

3. What is the expected market growth rate for allergy drugs?
   The global allergy market grows at a CAGR of roughly 4-6% through 2028.

4. Are there significant regional differences in pricing?
   Yes; prices are generally lower in countries with strong generic markets (India, Southeast Asia) and higher in the US/Europe, especially for OTC products.

5. What impact could regulatory changes have on pricing?
   Stricter approval procedures or pricing caps could constrain profit margins, whereas streamlined approvals and expanded OTC access can boost sales volume.

---

References

1. MarketResearch.com, "Global Allergy Therapeutics Market Size & Share Analysis," 2021.